Physician profile
Christopher L Walker
NPI 1326225822
$2,060.35
in general payments reported to CMS, 2019-2025
21 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $398 · 2021: $346 · 2022: $212 · 2023: $314 · 2024: $263 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $760.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.23 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $272.86 | 2019-2021 | |
| Lilly USA, LLC | $218.45 | 2020-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $194.88 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $146.48 | 2019-2025 | Farxiga |
| Amgen INC. | $99.18 | 2019-2025 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $99.14 | 2021-2024 | |
| Amarin Pharma, INC. | $90.57 | 2019-2021 | |
| Sanofi Pasteur INC. | $87.70 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.80 | 2019-2024 | Xifaxan |
| Pfizer INC. | $79.56 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $51.25 | 2023-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $37.09 | 2021 | |
| Biogen, INC. | $35.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.32 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $30.26 | 2020 | |
| Exact Sciences Corporation | $24.97 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $23.75 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.06 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.